Literature DB >> 26640084

Prognostic Impact of QRS Axis Deviation in Patients Treated With Cardiac Resynchronization Therapy.

Laura Perrotta1, Jagdesh Kandala2, Luigi DI Biase3, Alessandro Valleggi4, Federica Michelotti1,5, Paolo Pieragnoli1, Giuseppe Ricciardi1, Giosuè Mascioli5, Dhanunjaya Lakkireddy6, Jayasree Pillarisetti6, Michele Emdin4, Andrea Natale3, Jagmeet P Singh2, Luigi Padeletti1,7.   

Abstract

INTRODUCTION: QRS duration and morphology are currently recognized as recommended criteria for the selection of CRT candidates. It has recently been shown that patients with left bundle branch block (LBBB) derive substantial clinical benefit from CRT. The aim of this study is to investigate the prognostic impact of QRS axis deviation (AD) in HF patients with LBBB undergoing CRT. METHODS AND
RESULTS: We retrospectively evaluated 707 HF patients with LBBB who underwent CRT at five centers. Baseline QRS axis was defined as normal (NA: -30° to 90°), right axis deviation (RAD: 90° to 180°) and left axis deviation (LAD: <-30°). The primary endpoint was a composite of all cause death/HF hospitalization. The risk of endpoint by AD was evaluated with both Kaplan-Meier and Cox proportional hazard analysis. Among 707 patients (73% M, median age: 71 [62,77] years), 323 (46%) had NA, 359 (51%) LAD, and 25 (3.5%) RAD. Baseline clinical characteristics were similar between the three groups. Over a mean follow-up of 32 ± 25 months, 141 deaths occurred (21%) and 36% (n = 255) met with the composite endpoint. A significantly higher proportion of RAD patients (52%) reached the endpoint (LAD 40%, NA 30%). KM analysis showed that RAD and LAD patients had worse event free survival and in multivariate analysis both LAD (HR: 1.40; 95% CI: 1.05-1.86; P = 0.021) and RAD (HR: 2.49; 95% CI: 1.31-4.74; P = 0.005) were independently associated with worse clinical outcome.
CONCLUSIONS: Right or left axis deviation in the presence of LBBB in HF patients undergoing CRT are independent predictors of poor prognosis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  QRS axis deviation; cardiac resynchronization therapy; heart failure; left bundle branch block

Mesh:

Year:  2016        PMID: 26640084     DOI: 10.1111/jce.12887

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  5 in total

1.  Comparison of four LBBB definitions for predicting mortality in patients receiving cardiac resynchronization therapy.

Authors:  Marek Jastrzębski; Piotr Kukla; Roksana Kisiel; Kamil Fijorek; Paweł Moskal; Danuta Czarnecka
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-05-28       Impact factor: 1.468

2.  Influence of QRS duration and axis on response to cardiac resynchronization therapy in chronic heart failure with reduced left ventricular ejection fraction: A single center study including patients with left bundle branch block.

Authors:  Tomasz Fabiszak; Piotr Łach; Jakub Ratajczak; Marek Koziński; Wojciech Krupa; Jacek Kubica
Journal:  Cardiol J       Date:  2018-11-16       Impact factor: 2.737

3.  Impact of S-Wave Amplitude in Right Precordial Leads on Improvement in Mitral Regurgitation following Cardiac Resynchronization Therapy.

Authors:  Naoya Kataoka; Teruhiko Imamura; Takahisa Koi; Shuhei Tanaka; Nobuyuki Fukuda; Hiroshi Ueno; Koichiro Kinugawa
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-16

4.  Left Axis Deviation in Patients with Acute Heart Failure with Left Bundle Branch Block: Does It Really Matter?

Authors:  Eue Keun Choi
Journal:  Korean Circ J       Date:  2018-11       Impact factor: 3.243

5.  Prognostic Significance of Left Axis Deviation in Acute Heart Failure Patients with Left Bundle branch block: an Analysis from the Korean Acute Heart Failure (KorAHF) Registry.

Authors:  Ki Hong Choi; Seongwook Han; Ga Yeon Lee; Jin Oh Choi; Eun Seok Jeon; Hae Young Lee; Sang Eun Lee; Jae Joong Kim; Shung Chull Chae; Sang Hong Baek; Seok Min Kang; Dong Ju Choi; Byung Su Yoo; Kye Hun Kim; Myeong Chan Cho; Hyun Young Park; Byung Hee Oh
Journal:  Korean Circ J       Date:  2018-11       Impact factor: 3.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.